⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SYRE News
Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
globenewswire.com
SYRE
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Form 8-K
sec.gov
SYRE
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
globenewswire.com
SYRE
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
globenewswire.com
SYRE
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
globenewswire.com
SYRE